| 货号 | 规格 | 价格 | 上海 | 北京 | 珠海 | 南京 | 武汉 | 购买数量 |
|---|---|---|---|---|---|---|---|---|
S81103-1mg |
99.10% | ￥300.00 |
5 | - | - | - | - |
|
S81103-2mg |
99.10% | ￥500.00 |
8 | - | - | - | - |
|
S81103-5mg |
99.10% | ￥750.00 |
8 | - | - | - | - |
|
S81103-10mg |
99.10% | ￥1150.00 |
6 | - | - | - | - |
|
S81103-25mg |
99.10% | ￥2400.00 |
2 | - | - | - | - |
|
S81103-50mg |
≥99% | ￥3700.00 |
货期：2-3天 | - | - | - | - |
|
S81103-100mg |
≥99% | ￥6500.00 |
货期：2-3天 | - | - | - | - |
|
| 产品描述： | Evofosfamide (TH-302) is a hypoxia-activated prodrug with IC50 of 10 μM and 1000 μM in hypoxia (N2) and normoxia (21% O2), respectively. | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 靶点： | Hypoxia-activated prodrug;Apoptosis; Others | ||||||||||||||||||||
| 体内研究： | Evofosfamide (TH-302) is a hypoxia-activated prodrug known to activate selectively under the hypoxic conditions commonly found in solid tumors. The mean values of normalized Ktrans decrease 69.2% for Evofosfamide (TH-302)-treated mice in Hs766t tumors, decrease 46.1% for Mia PaCa-2 tumors and increase 4.9% in SU.86.86 tumors. Both changes for Hs766t and Mia PaCa-2 treatment groups are statistically significant (P<0.01) when compare to their own control group. A significant reduction in the hypoxic fraction (HF) to 2.1%±4.7% is seen after 95% oxygen breathing (P<0.001), whereas 7% oxygen breathing significantly increase the HF to 29.5%±14.7% (P=0.029). Exposing rhabdomyosarcoma-bearing rats to increasing oxygen conditions abolish the effect of TH-302 and reduce the T4×SV from 20.4±3.5 to 15.3±2.5 days (P=0.007), whereas control animals have an increased T4×SV. Upon combination with radiotherapy, the T4×SV of TH-302-treated tumors decrease from 30.8±5.9 (Evofosfamide (TH-302)+radiotherapy) to 25.7±2.9 days (Evofosfamide (TH-302)+radiotherapy+95% O2). | ||||||||||||||||||||
| 参考文献： | 1. Meng F, et al. Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition. BMC Cancer. 2015 May 21;15:422. 2. Zhang X, et al. MR Imaging Biomarkers to Monitor Early Response to Hypoxia-Activated Prodrug TH-302 in Pancreatic Cancer Xenografts. PLoS One. 2016 May 26;11(5):e0155289. 3. Peeters SG, et al. TH-302 in Combination with Radiotherapy Enhances the Therapeutic Outcome and Is Associated with Pretreatment [18F]HX4 Hypoxia PET Imaging. Clin Cancer Res. 2015 Jul 1;21(13):2984-92. | ||||||||||||||||||||
| 溶解性： | DMSO : 94 mg/mL (209.34 mM; Need ultrasonic and warming) H2O : 4.35 mg/mL (9.69 mM; ultrasonic and warming and heat to 60°C) | ||||||||||||||||||||
| 保存条件： | -20℃ | ||||||||||||||||||||
| 配置溶液浓度参考： |
|
||||||||||||||||||||
| 注意： | 部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
沪公网安备 31011702002021号
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京